chromatography-tandem mass spectrometry. Visuoconstructional abilities, visual memory, and processing speed at baseline and follow-up were assessed using the ReyOsterrieth Complex Figure Test ( Nutr (2017Nutr ( ) 56:2093Nutr ( -2103 1 3 a smaller decline in the DSST (β = 0.007, p = 0.020). Men with low 25(OH)D levels (<50 nmol/l) showed a greater decline in the CTRM compared to men with higher (≥75 nmol/l) levels (β = −0.41, p = 0.035). However, these associations disappeared after adjusting for confounders such as depressive symptoms, BMI, and comorbidities. There was no indication of a relationship between 1,25(OH) 2 D and decline in cognitive subdomains. Conclusion We found no evidence for an independent association between 25(OH)D or 1,25(OH) 2 D levels and visuoconstructional abilities, visual memory, or processing speed over on average 4.4 years in this sample of middleaged and elderly European men.
Introduction
Vitamin D inadequacy is common in Europe and in the USA with prevalence estimates increasing with age and ranging from 40 to 100 % in the community-dwelling elderly population [1, 2] . Low vitamin D levels have been reported to be associated with various negative health outcomes, including osteomalacia, cancer, hypertension, and diabetes [3] . Recently, vitamin D has been recognized as a neuroactive steroid and as such can potentially influence cognitive functioning and decline [4] . The physiological plausibility of this relationship is supported by findings that vitamin D is involved in axonal growth [5] , brain calcium metabolism [6] , and brain cell differentiation [7] . In addition, vitamin D has been shown to stimulate phagocytosis and clearance of amyloid-β in the brain, one of the primary hallmarks of Alzheimer's disease [8] . In accordance with these possible biological pathways, research has indicated that lower vitamin D levels are associated with a greater risk of developing Alzheimer's disease and all-cause dementia [9] . However, evidence from both animal and human behavioural studies towards the role of vitamin D on cognition has been inconsistent. To date, over 30 crosssectional studies have investigated the association between cognitive functions and 25-hydroxyvitamin D [25(OH)D], the main measure of vitamin D status. Most, but not all, of these studies reported a positive relationship between 25(OH)D and cognition [10, 11] . However, research in this field has been criticized for insufficient adjustment for confounding variables, small sample sizes, and the use of suboptimal methods for measuring 25(OH)D [12] . Moreover, prospective studies have reported mixed results regarding vitamin D and cognitive decline. Although four longitudinal studies have shown a significant association between lower vitamin D levels and decline in global cognition [13] [14] [15] [16] , and/or specific domains such as executive function [13] and attention [16] , three major investigations were unable to find any association [17] [18] [19] . There is some evidence to suggest that the effects of vitamin D on cognition are gender specific, with two studies finding more pronounced associations in women than in men [20, 21] . It therefore remains to be determined whether vitamin D affects cognitive change over time in men, and many researchers have called for the development of more welldesigned prospective studies on the relationship between vitamin D status and cognitive decline [22, 23] .
The European Male Ageing Study (EMAS) is a multicentre population cohort study which assessed changes in physical and cognitive functioning of a large group of middle-aged and elderly men over a period of 4.4 years [24] . Cross-sectional analyses of the baseline measurements indicated that 25(OH)D levels were positively associated with cognitive processing speed [25] . In addition, it was found that the impact of vitamin D on cognition may be more pronounced in individuals with 25(OH)D levels below 35 nmol/l and men over the age of 60 [24] . In the present study, we aimed to investigate whether vitamin D status could predict decline in visuoconstructional abilities, visual memory, and processing speed using longitudinal data from EMAS. Secondly, it was our objective to examine a potential interaction between age and vitamin D on cognitive functions. Nearly all of the previous longitudinal studies have focused on adults aged 65 and over [13, 16, 17] . The only study that involved participants in late middle age (45-65 years) found no association between 25(OH)D levels and cognitive decline or risk of dementia [18] . It is therefore possible that maintaining an optimal vitamin D level is particularly important for older adults. As the current study included elderly as well as middle-aged men, we were able to compare the effects of vitamin D deficiency on cognition across a wide age range. Finally, a unique feature of this study was that levels of 1,25-dihydroxyvitamin D [1, 25(OH) 2 D], the active metabolite of 25(OH)D, were also analysed. This metabolite, in contrast with 25(OH)D, directly induces responses of the vitamin D receptors and mediates transcriptional regulation of several genes [26] . It has been suggested that 1,25(OH) 2 D may be useful as a marker of various health outcomes [27, 28] . This is the first study to examine 1,25(OH) 2 D as a potential marker of cognitive decline.
Methods

Participants
Participant recruitment, study design, and assessments of EMAS have previously been described in detail [24] . Briefly, 8416 community-dwelling men aged 40-79 years were invited to attend a screening at a local clinic. A short questionnaire was used to gather information on sociodemographic, general health, and lifestyle factors. The 3369 men who agreed to participate subsequently visited a research clinic to complete several interviewer-assisted questionnaires and undergo physical and cognitive assessments. The participating centres were based in Leuven 
Assessments
Demographic information and details on comorbidities, smoking, and alcohol consumption were collected using the postal questionnaire. The interviewer-assisted questionnaire included questions about general health, the Physical Activity Scale for the Elderly (PASE) [29] , and Beck's Depression Inventory II (BDI) [30] to assess the presence and severity of depressive symptoms. Reuben's Physical Performance Test (PPT) [31] was employed to measure physical function. Information on prescription and non-prescription medications was obtained by self-report.
Tests of cognitive function
Cognitive testing was carried out at baseline and during follow-up assessments. The EMAS cognitive test battery consisted of tasks measuring components of fluid intelligence.
Tests were specifically selected for minimal cultural and linguistic influences and were standardized across centres. The cognitive tasks used were (in order of administration): the Rey-Osterrieth Complex Figure (ROCF) Copy and Recall tests, the Camden Topographical Recognition Memory (CTRM) test, and the Digit Symbol Substitution Test (DSST). Higher scores on each test reflect better cognitive performance of the participant. In the ROCF Copy task, participants are required to copy an abstract two-dimensional figure as accurately as possible within 5 min. This test provides an indication of visuoconstructional abilities and visual memory [32] . In the ROCF recall component, participants are asked unexpectedly to draw the figure from memory 30 min after completing the Copy task. The ROCF scoring criteria used in this study are based on Osterrieth's original test procedure, with a maximum score of 36 for both the Copy and Recall subtests. The CTRM was used to assess visual recognition memory [33] and involved the presentation of photographs of urban scenes followed by a forced-choice recognition component. Each correctly identified image is awarded with one point, with a maximum score of 30. Finally, cognitive processing speed and visual scanning were measured using the DSST [34] . In this timed paper-and-pencil subtest from the Wechsler Adult Intelligence Scale III, participants are asked to substitute as many symbols for digits as possible within 60 s using a coding table.
25(OH)D and 1,25(OH) 2 D assays
In the baseline phase, morning phlebotomy was performed before 10 AM to obtain a fasting blood sample from all participants. Once processed, the serum was stored at −80 °C and shipped on dry ice to a central laboratory in Leuven, Belgium. A radioimmunoassay kit was used to determine total serum 25(OH)D levels (RIA kit; DiaSorin, Stillwater, MN, USA). Intra-and interassay coefficients for 25(OH) D levels were 11 and 9 %, respectively. 1,25(OH) 2 D concentration was measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Detailed methodology of the 1,25(OH) 2 D measurements has previously been described by Vanderschueren and colleagues [35] .
Analyses
The data were analysed using the statistical programme Stata version 13.1 (StataCorp LP, College Station, TX, USA). Participants with missing 25(OH)D and/or cognitive data were excluded from the analyses. Continuous cognitive decline in the ROCF copy and recall, CTRM, and DSST was analysed as a continuous as well as a categorical variable to allow for a possible nonlinear association with cognitive decline as suggested by previous studies [11, 20] . There is no established cut-off value for defining vitamin D deficiency in relation to cognition, leading to different 25(OH)D deficiency thresholds being used in studies of cognitive function. This heterogeneity in definitions of vitamin D sufficiency has made it difficult to compare results from different studies in the past. Following recommendations from Annweiler and colleagues [22] , we looked at three commonly used thresholds. 25(OH)D was classified as deficient (<25 nmol/l), insufficient (25-49 nmol/l), suboptimal (50-74 nmol/l), and sufficient (≥75 nmol/l). 1,25(OH) 2 D concentration was examined as a continuous variable. For the covariates, age (years), age left education (years), BMI (kg/m 2 ), BDI score, PASE score, and PPT rating were analysed as continuous variables. Centre, tobacco use (currently smoking vs. non-smoking), alcohol consumption (≥1 day/week vs. <1 day/week), season at which the blood test was taken at baseline [winter (Jan-March), spring (April-June), summer (July-Sept), and autumn (Oct-Dec)], and comorbidities (0,1, or ≥2) were included as categorical variables. The comorbidities assessed were heart conditions, high blood pressure, stroke, diabetes, liver and kidney conditions, bronchitis, and cancer.
The association between 25(OH)D level and cognitive decline was initially evaluated graphically using the locally weighted scatterplot smoothing (LOWESS) technique [36] . As this outlier-resistant method makes no assumptions about the form of the relationship, the resulting regression lines can provide information about nonlinear associations between variables. Age-adjusted multiple linear regressions were then performed with continuous change on all four cognitive tests as the outcome variables and continuous 25(OH)D, categories of 25(OH)D, or continuous 1,25(OH) 2 D at baseline as the predictor. Subsequently, intermediate models were created adjusting for age, subjective depressive symptoms, season, and centre. Finally, full models were fitted with further adjustments for education, physical activity and performance, comorbidities, and lifestyle factors. Interaction terms between age by decade and 25(OH)D or 1,25(OH) 2 D level were added to the full models to assess differences across age groups in the relationship between cognitive decline and vitamin D status. As it has been suggested that low vitamin D levels increase the risk of depression [37, 38] , which in turn could negatively affect cognitive functions [39] , an interaction term between BDI score and 25(OH)D levels was included in the models to assess potential moderation effects. Finally, participants taking vitamin D and/or calcium supplements at baseline were excluded and the above analyses repeated using the remaining sample. Results are expressed as unstandardized β-coefficients and 95 % confidence intervals.
Results
Subjects
Of the 2736 men returning for follow-up assessments, 105 participants were excluded from the analyses due to missing 25(OH)D measurements. Two participants with 25(OH) D levels above 250 nmol/l were removed from the dataset, as these values exceed the upper limit of the normal range [40] . A total of 199 participants with missing CTRM and DSST data and 527 participants with missing ROCF data were omitted, leaving a sample of 2430 men in the CTRM and DSST analyses and 2102 men in the ROCF Copy and Recall models. For the 1,25-dihydroxyvitamin D analyses, 408 men with missing 1,25(OH) 2 D information, 190 men with missing CTRM and DSST scores, and 517 men with missing ROCF scores were excluded. The final sample consisted of 2138 participants in the CTRM and DSST analyses and 1811 participants in the ROCF analyses. Baseline characteristics of the participants are listed in Table 1 . Overall, the mean age of the study population (N = 2430) was 59.0 years, average BMI was 27.6, and 41.9 % of the participants had one or more comorbidities.
Cognition and vitamin D status in EMAS
The mean cognitive scores at baseline and follow-up are shown in Table 1 . Mean scores on the ROCF Recall (t(2101) = 4.617, p < 0.001) and CTRM (t(2429) = 3.002, p = 0.003) improved between the two assessments, whereas participants on average showed a decrease in performance on the DSST (t(2429) = −12.120, p < 0.001). There was no significant change in mean score on the ROCF Copy (t(2101) = 0.042, p = 0.966). A cognitive decline of ≥1 SD from baseline was observed for 161 (7.6 %) men on the ROCF Copy, 282 (13.4 %) men on the ROCF Recall, 329 (13.5 %) men on the CTRM, and 359 (14.8 %) men on the DSST. Independent t tests indicated that participants who returned for follow-up had higher baseline cognitive scores than those who were lost to follow-up (all p < 0.001). Linear regressions showed that older age, fewer years of education, higher BDI scores, lower physical activity and performance, and smoking were associated with greater decline in one or more cognitive tasks in the study sample (Table 3) . Kruskal-Wallis tests revealed that change on all four cognitive test scores over time differed significantly between the centres (all p < 0.001).
The 
25(OH)D, 1,25(OH) 2 D and decline in cognitive subdomains
Age-adjusted LOWESS plots revealed no clear associations between 25(OH)D level at baseline and decline in the four cognitive tasks (Fig. 1) . Results from the multiple linear regression models exploring the relationship between continuous 25(OH)D and cognitive decline are displayed in Table 3 . In age-adjusted models, higher 25(OH)D concentrations were associated with a smaller decline in DSST performance over time. However, this association was not maintained in intermediate models or when models were fully adjusted for covariates. Age-adjusted multiple regression analyses of categorical 25(OH)D status indicated that participants with vitamin D deficiency showed a greater decline in the DSST than participants with sufficient vitamin D levels. In addition, vitamin D insufficiency was associated with greater cognitive decline on the CTRM compared with sufficient vitamin D status. Both associations again disappeared when models were adjusted for additional covariates (Table 4 ). There were no significant associations between 1,25(OH) 2 D and cognitive decline in age-adjusted, intermediate, or fully adjusted models (Table 3 ). There was no evidence for a significant interaction between 25(OH)D or 1,25(OH) 2 D level and age in any of the models (all p > 0.05). The interaction effects of BDI score and vitamin D levels on cognitive change scores were not significant (data not shown). These findings indicate that depressive symptoms did not have a moderating effect on the relationship between vitamin D and cognitive change in this sample. The results were unchanged when participants reporting vitamin D or calcium supplements intake were excluded from the regression analyses.
Discussion
In this multicentre prospective study of middle-aged and elderly European men, we found no evidence for any association between vitamin D status and subsequent cognitive decline in several domains, including processing speed, visual memory, and visuospatial learning. Contrary to our expectations, we found no interaction effects of age and 25(OH)D concentration on cognitive abilities. These results differ from our previous cross-sectional findings that indicated a positive association between 25(OH)D levels and processing speed, particularly in men over the age of 60 years [25] . Although decline in the DSST was associated with both continuous 25(OH)D level and deficient vitamin D status in the age-adjusted models in the present analyses, this association was not maintained when further adjusted for confounding variables. Similarly, the association between decline on the CTRM and insufficient 25(OH) D status was significant in age-adjusted, but not in further adjusted models. No significant associations were found between 1,25(OH) 2 D and cognitive decline. Our findings are consistent with results from the Osteoporotic Fractures in Men Study (MrOS), which suggested that slight associations between 25(OH)D and decline in global cognition or executive function over 4.6 years in elderly men were mainly caused by confounding variables such as educational level [19] . Previous studies with insufficient adjustment for covariates may therefore have overestimated the strength of the relationship between vitamin D and cognition. Another possibility is that the mixed findings of positive associations [13] [14] [15] [16] and null results [17] [18] [19] in earlier longitudinal investigations are due to gender differences, as some studies suggest that the beneficial cognitive effects of high vitamin D levels are more pronounced in women than in men [20, 21] . This would explain the lack of significant findings in both EMAS and the MrOS cohort. However, a large-scale observational study of elderly women was also unable to find significant associations between vitamin D and cognitive decline over 6 years [17] . Thus, there is no conclusive evidence that vitamin D status affects cognition more in women than in men. Alternatively, it could be argued that the testing interval of 4.4 years in the current study was too short to uncover small effects of 25(OH)D on cognitive deterioration. This especially concerns middle-aged participants, as they are less likely to demonstrate rapid and marked cognitive decline compared with older adults. Biological risk factors are sometimes present for a substantial period of time before they have an impact on cognition. For example, neurofibrillary tangles and senile plaques associated with Alzheimer's disease start to accumulate around the age of thirty in some individuals [41] while clinical changes generally do not appear until old age. Similarly, it is possible that chronic vitamin D deficiency in midlife only leads to increased risk of cognitive decline several years or even decades later. As other longitudinal studies spanning three to five years did report a relationship between cognitive decline and serum 25(OH)D [14] [15] [16] , however, we expected that the time frame of our investigation would be sufficient to detect such associations. As our study sample was relatively young, cognitive deterioration may have been smaller than in studies of elderly individuals, making it more difficult to detect associations with vitamin D levels. However, interaction terms for 25(OH)D or 1,25(OH) 2 D levels, age by decade, and cognition showed that even in the oldest age group (≥70 years) there was no significant relationship between vitamin D and cognitive decline. It is therefore improbable that the null findings are caused entirely by the young age of this population compared to other longitudinal studies. Another explanation may be that, although the tasks used here assessed a range of cognitive functions, other domains such as language skills or attention are more strongly affected by vitamin D. Previous research, however, has found no association between vitamin D concentration and verbal memory [22] or verbal fluency [42] , whereas visuospatial abilities [13, 21, 43] and processing speed [25, 43, 44] were correlated with serum 25(OH)D levels in several studies. Finally, it has been suggested in cross-sectional research of the oldest that the relationship between vitamin D levels can be described by an inverse U-shape rather than linearly [16] . It is therefore possible that only samples including both very low and very high ranges are able to examine this 2 nmol/l, we were able to investigate this possibility in middle-aged and older adults. However, there was no evidence for a curvilinear relationship between vitamin D and cognitive decline in the LOWESS plots for this sample of adults between the ages of 40 and 83 years. Additional longitudinal research may further explore potential differences in the associations of vitamin D and cognition in different age groups. Consistent with our results, there is presently little evidence from clinical studies that increasing vitamin D levels improves cognition. Although animal models have suggested that vitamin D supplementation positively affects brain energy metabolism and cognitive decline [45] , this finding has not yet been confirmed by clinical trials involving healthy human adults. A study of 128 young adults receiving daily capsules of 5000 IU vitamin D or placebo found no difference in cognitive functioning between the groups after 6 weeks of supplementation [46] . This study was possibly underpowered due to its small sample size and relatively short administration of supplements. However, another investigation of 4142 older women found that taking one tablet of 400 IU vitamin D and 1000 mg of calcium carbonate per day for 7.8 years did not lead to slower cognitive decline or lowered risk of dementia compared to a placebo [47] . In both studies, the majority of the participants had sufficient vitamin D levels at baseline. It is possible that clinical trials focusing on individuals with deficient vitamin D status at baseline would produce different results. Further investigations using vitamin D supplements without additional nutrients in diverse populations are therefore needed to conclusively determine the role of serum 25(OH)D in cognitive functioning. Nevertheless, our current findings suggest that an increase in vitamin D concentration is unlikely to affect cognitive ageing.
Strengths and weaknesses
A main strength of the European Male Ageing Study is the broad range of multidisciplinary data collected. Due to extensive physiological assessments, we were able to adjust for critical confounders such as education, general health, depressive symptoms, and BMI. Furthermore, this is the first longitudinal study to include middle-aged as well as elderly men, which allowed us to examine the effects of vitamin D across different age groups. In contrast with previous studies, we also used multiple thresholds to identify participants with deficient, insufficient, suboptimal, or sufficient vitamin D status. As there is not yet an established cut-off value for vitamin D deficiency with regards to cognition, investigations like the present one can provide valuable information for future clinical trials [23] . Finally, this is the first investigation of vitamin D and cognitive abilities to include measurements of 1,25(OH) 2 D. A possible limitation of the present study is that measurements of vitamin D concentrations were only obtained at baseline. Although it has been suggested that 25(OH)D levels remain stable over periods as long as 14 years [48] , baseline measurements may not reflect vitamin D status at follow-up. We were therefore unable to investigate the relationship between changes in vitamin D levels and measured cognitive subdomains. Finally, the ROCF Copy showed a ceiling effect and may lack sensitivity for assessing cognitive deterioration in this relatively healthy population. Another potential limitation is that no alternate forms were used for the cognitive tasks, and it is therefore probable that practice effects influenced follow-up performance on the ROCF Recall and CTRM, leading to potential underestimations of cognitive decline. Practice effects did not obscure decreased performance fully, as a substantial number of the participants (ranging from 7.6 to 14.8 %) showed a decline of 1 SD or more on the cognitive tasks. In addition, repeated testing is not expected to have affected results on the DSST, as this task is minimally if at all subject to learning effects [49] . Therefore, we were still able to examine potential associations between vitamin D levels and decline in cognitive subdomains with age. However, it is acknowledged that the absence of alternate forms of the ROCF and CTRM is likely to limit our sensitivity to detect small but significant declines in visuoconstructional abilities and memory. Considering these limitations, the present results need to be interpreted with care.
Conclusion
In this cohort of middle-aged and older European men, we found no relationship between 25(OH)D or 1,25(OH) 2 D levels and specified domains of cognitive decline. Weak associations between 25(OH)D and processing speed or visual memory were explained by factors such as comorbidities and adverse lifestyle factors. The current findings are in line with several prospective studies and human clinical trials that failed to find associations between vitamin D and cognitive decline. Further well-designed longitudinal and interventional studies of longer duration, including more cognitive domains and both genders, may be needed to clarify the relationship between 25(OH)D status and cognition. Based on our results, however, vitamin D levels do not appear to be markedly associated with visuoconstructional abilities, visual memory, and processing speed in ageing men.
